Clinical trials: Bipolar I Depression
Mental Disorder, Schizophrenia
A Trial to Assess a Wearable Patch's Functioning to Detect Medication Ingestion
The primary purpose of the study is to evaluate the positive detection accuracy (PDA) and detection latency measures of the D-Tect patch.
- Conditions
- Mental Disorder, Schizophrenia, Major Depressive Disorder, Bipolar I Disorder
- Trial name
- NCT06372210
- Testing
- Abilify MyCite®, D-Tect Patch
- Where
- United States
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Bipolar Depression
Proof Of Mechanism Study To Determine Efficacy Of PF-04455242 In Blocking Spiradoline (PF-00345768) Stimulated Prolactin Release
This study will be a Proof of Mechanism (POM) study to establish evidence of central pharmacodynamic activity for PF 04455242, and will be a parallel group, randomized, double blind, sponsor open study conducted in healthy male…
- Trial name
- NCT00988949
- Testing
- PF-04455242, spiradoline
- Where
- Singapore
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Pfizer
Gut Microbiome, Gastrointestinal Microbiome
A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Disease
This study seeks to correlate microbiome sequencing data with information provided by patients and their medical records.
- Conditions
- Gut Microbiome, Gastrointestinal Microbiome, Autism, Autism Spectrum Disorder
- Trial name
- NCT04031469
- Testing
- There is no intervention in this study
- Where
- United States
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- ProgenaBiome
Bipolar Disorder, Bipolar I Disorder
Using Neuroplasticity-Based Computerized Training to Improve Emotion Regulation in Bipolar Disorder (BRAINS)
The goal of this study is to evaluate the feasibility and potential benefit of a behavioral intervention designed to improve emotion regulation in individuals with bipolar disorder.
- Conditions
- Bipolar Disorder, Bipolar I Disorder, Bipolar Affective Disorder, Bipolar Disorder I
- Trial name
- BRAINS (NCT05683431)
- Testing
- Cognitive Control of Emotion (CCE) Training
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Rush University Medical Center
Anxiety, Depression
Ginger.io Behavioral Health Study
This Study will evaluate the impact of a smartphone-based platform on a range of outcomes for medically-underserved patients with mood disorders (e.g.
- Conditions
- Anxiety, Depression, Bipolar I Disorder, Bipolar II Disorder
- Trial name
- NCT02491307
- Testing
- Ginger.io Smartphone Application
- Where
- 4 sites in United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Community Health Center, Inc.
Depressive Disorder, Major, Bipolar Disorder
Psychiatric Genotype/Phenotype Project Repository
The purpose of this project is to obtain DNA, brain imaging data, other biological samples (e.g., urine, serum), and a comprehensive clinical assessment on patients with schizophrenia and other psychotic disorders, bipolar…
- Conditions
- Depressive Disorder, Major, Bipolar Disorder, Psychotic Disorders
- Trial name
- PGPP (NCT00762866)
- Where
- United States
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- Vanderbilt University
Bipolar Disorder
Double-blind, Placebo-Controlled Divalproex Sodium ER in Bipolar I or Bipolar II Depression
Double-Blind, Placebo-Controlled Divalproex Sodium ER in Bipolar I or Bipolar II Depression Previously Diagnosed and Treated as Recurrent Major Depression: This study recruits males and females aged 18 - 70 who currently meet…
- Trial name
- NCT00194116
- Testing
- Divalproex Sodium ER
- Where
- United States
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- University Hospitals Cleveland Medical Center
Major Depressive Disorder, Bipolar Disorder
Naturalistic Study of Ketamine in the Treatment of Depression
This study aims to examine the effect of ketamine in decreasing the risk of suicide in patients with depression and its effectiveness as an antidepressant agent.
- Conditions
- Major Depressive Disorder, Bipolar Disorder, Bipolar Depression, Bipolar I Disorder
- Trial name
- NCT05249309
- Testing
- Ketamine
- Where
- 2 sites in Brazil
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Hospital de Clinicas de Porto Alegre
Depression
Brain Network Activation Analysis to Diagnose/Assess Treatment of Unipolar Major Depression and Bipolar I Depression
The investigators are conducting this study to test the usefulness of a new type of analysis of electroencephalographic (EEG) recordings called brain network activation or BNA.
- Trial name
- BNA-Mood (NCT01683214)
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Rush University Medical Center
Bipolar Depression
Brexpiprazole Treatment for Bipolar I Depression
Bipolar disorder (BD) is a frequent and lifelong recurrent mood disorder with treatment-resistant depressive episodes. Importantly, depressive symptoms and cognitive decline are major determinants of functionality and quality of…
- Trial name
- NCT04569448
- Testing
- Brexpiprazole
- Where
- 3 sites in Canada
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- Douglas Mental Health University Institute
Smoking Cessation, Cigarette Smoking
Treating Smokers With Mental Illness
This is a smoking cessation study that will enroll smokers who have been diagnosed with a severe mental illness. The study will use a combination of intensive tobacco treatment counseling and nicotine replacement therapy to…
- Conditions
- Smoking Cessation, Cigarette Smoking, Schizophrenia, Psychotic Disorders
- Trial name
- NCT03822416
- Testing
- Nicotine patch, Nicotine lozenge, Therapy
- Where
- United States
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- University of Minnesota
Major Depressive Disorder, Bipolar I Disorder
Digital Phenotypes for Predicting Depression_Validation
This 12-month, single-site prospective observational study will prospectively monitor the recurrence of mood episodes while continuously collecting passive digital phenotypes in individuals with and without mood disorders.
- Conditions
- Major Depressive Disorder, Bipolar I Disorder, Bipolar II Disorder, Mood Disorders
- Trial name
- NCT07880015
- Where
- South Korea
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Korea University Anam Hospital
Bipolar Disorder, Bipolar I Depression
Lithium Effects on the Brain's Functional and Structural Connectome in the Treatment of Bipolar Disorder
Lithium is highly effective in the treatment of bipolar disorder. This study aims to investigate, for the first time, the impact of lithium monotherapy on the structural and functional connectivity of the brain using MRI imaging.
- Conditions
- Bipolar Disorder, Bipolar I Depression, Bipolar II Depression, Bipolar Depression
- Trial name
- NCT03336918
- Testing
- Lithium
- Where
- United States
- Volunteers
- 81 people, healthy volunteers welcome
- Sponsor
- Brigham and Women's Hospital
Bipolar, Depression
Adjunctive Lisdexamfetamine (LDX) in Bipolar Depression
The specific aim of this study is to evaluate the efficacy and tolerability of lisdexamfetamine in the adjunctive treatment of bipolar disorder.
- Trial name
- NCT01131559
- Testing
- Lisdexamfetamine
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Lindner Center of HOPE
Major Depressive Disorder, Bipolar I and Bipolar II
Microbiome of Depression & Treatment Response to Citalopram
The purpose of this study is to evaluate the feasibility of developing a microbiome probe of depression and to evaluate the microbiome change in a preliminary analysis of treatment response (n=20) vs.
- Trial name
- NCT02330068
- Testing
- citalopram
- Where
- 2 sites in United States
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Bipolar Disorder
Single Ascending Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD4451
This is a single ascending dose study to assess the safety, tolerability and pharmacokinetics of AZD4451.
- Trial name
- AZD4451 SAD (NCT01196676)
- Testing
- AZD4451
- Where
- United States
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Mood Disorders, Major Depressive Disorder
Unobtrusive Monitoring of Affective Symptoms and Cognition Using Keyboard Dynamics (UnMASCK)
Mood disorders are associated with significant financial and health costs for the United States, partially due to cognitive problems in these patients that can worsen disease course and impair treatment response.
- Conditions
- Mood Disorders, Major Depressive Disorder, Bipolar Disorder I, Bipolar Disorder II
- Trial name
- UnMASCK (NCT04358900)
- Where
- United States
- Volunteers
- 132 people, healthy volunteers welcome
- Sponsor
- University of Illinois Chicago